Related references
Note: Only part of the references are listed.Evaluation and Management of Neuroendocrine Tumors of the Pancreas
Aaron T. Scott et al.
SURGICAL CLINICS OF NORTH AMERICA (2019)
Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium
Andrea Mafficini et al.
JOURNAL OF ENDOCRINOLOGY (2018)
mTOR signalling and cellular metabolism are mutual determinants in cancer
Dirk Mossmann et al.
NATURE REVIEWS CANCER (2018)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton et al.
CELL (2017)
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao et al.
LANCET (2016)
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors
Timothy J. Hobday et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Therapeutic uses of somatostatin and its analogues: Current view and potential applications
Uma Rai et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Martyn E. Caplin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Prognostic Significance of MTOR Pathway Component Expression in Neuroendocrine Tumors
Zhi Rong Qian et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Current Scientific Rationale for the Use of Somatostatin Analogs and mTOR Inhibitors in Neuroendocrine Tumor Therapy
Corinne Bousquet et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs
Isabel Fernandes et al.
ONCOTARGETS AND THERAPY (2012)
The Tumor Suppressor Protein Menin Inhibits AKT Activation by Regulating Its Cellular Localization
Yan Wang et al.
CANCER RESEARCH (2011)
The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors
Ben Lawrence et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2011)
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
Yuchen Jiao et al.
SCIENCE (2011)
VEGF Secretion by Neuroendocrine Tumor Cells Is Inhibited by Octreotide and by Inhibitors of the PI3K/AKT/mTOR Pathway
Karine Villaume et al.
NEUROENDOCRINOLOGY (2010)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Rationale for the use of somatostatin analogs as antitumor agents
C. Susini et al.
ANNALS OF ONCOLOGY (2006)
RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells
JY Yu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
